Literature DB >> 16990205

The Short Health Scale: a valid measure of subjective health in ulcerative colitis.

Henrik Hjortswang1, Gunnar Järnerot, Bengt Curman, Hanna Sandberg-Gertzén, Curt Tysk, Björn Blomberg, Sven Almer, Magnus Ström.   

Abstract

OBJECTIVE: Assessment of health-related quality of life (HRQOL) is important in both clinical practice and clinical trials, and several multi-item questionnaires are currently in use. We have devised and evaluated a simplified four-item questionnaire, the Short Health Scale (SHS), representing each of four health dimensions: (a) symptom burden, (b) social function, (c) disease-related worry and (d) general well-being.
MATERIAL AND METHODS: Three hundred patients with ulcerative colitis completed the SHS and three other HRQOL questionnaires (IBDQ, RFIPC and PGWB). Half of the patients repeated the questionnaires after 6 months - or earlier if disease activity changed. Test-retest reliability was derived from measurements of the SHS questions, 2 weeks apart, on 18 patients in remission.
RESULTS: Patients in relapse scored higher on each of the four SHS questions than patients in remission (p < 0.001). Each of the four SHS scores were associated with results of their corresponding health dimension obtained with the other three questionnaires (rs=0.57-0.78, p < 0.001) (validity). The results of the SHS proved stable on repeated measurement with a 2-week interval in patients in remission (rs=0.71-0.91, p < 0.01) (test-retest reliability). Patients with a change in disease activity had a significant change in their SHS scores (p < 0.05) (responsiveness).
CONCLUSIONS: The SHS is a valid, reliable and responsive measure of subjective health in patients with ulcerative colitis. It is simple to administer, quickly completed and the results do not need further calculations. The SHS can be used in clinical trials and in clinical practice to identify the patient's main problems affecting health.

Entities:  

Mesh:

Year:  2006        PMID: 16990205     DOI: 10.1080/00365520600610618

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  31 in total

1.  Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS).

Authors:  Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Bjørn Moum
Journal:  Qual Life Res       Date:  2011-12-07       Impact factor: 4.147

2.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 3.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

4.  Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

Authors:  Anders Lasson; Lena Öhman; Per-Ove Stotzer; Stefan Isaksson; Otto Überbacher; Kjell-Arne Ung; Hans Strid
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

5.  Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.

Authors:  Annelie Lindberg; Michael Eberhardson; Mats Karlsson; Per Karlén
Journal:  BMC Gastroenterol       Date:  2010-07-06       Impact factor: 3.067

Review 6.  Microscopic colitis.

Authors:  Kristin E Burke; Mauro D'Amato; Siew C Ng; Darrell S Pardi; Jonas F Ludvigsson; Hamed Khalili
Journal:  Nat Rev Dis Primers       Date:  2021-06-10       Impact factor: 52.329

7.  Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Authors:  Axel Dignass; Robert Schnabel; Jacek Romatowski; Vladimir Pavlenko; Andrey Dorofeyev; Jelena Derova; Laimas Jonaitis; Karin Dilger; Tanju Nacak; Roland Greinwald
Journal:  United European Gastroenterol J       Date:  2017-03-30       Impact factor: 4.623

8.  Prototype evaluation of a self-management Internet diary for patients with ulcerative colitis.

Authors:  Lucia Snoei; Ad van Bodegraven; Bas Oldenburg; Theo Stijnen; Ad A Kaptein
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.

Authors:  Carl Eriksson; Sara Rundquist; Vyron Lykiardopoulos; Ruzan Udumyan; Per Karlén; Olof Grip; Charlotte Söderman; Sven Almer; Erik Hertervig; Jan Marsal; Jenny Gunnarsson; Carolina Malmgren; Jenny Delin; Hans Strid; Mats Sjöberg; David Öberg; Daniel Bergemalm; Henrik Hjortswang; Jonas Halfvarson
Journal:  Therap Adv Gastroenterol       Date:  2021-07-03       Impact factor: 4.409

10.  Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.

Authors:  Nienke Lesuis; Ragnar Befrits; Filippa Nyberg; Ronald F van Vollenhoven
Journal:  BMC Med       Date:  2012-08-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.